News
NAVB
0.2706
-3.36%
-0.0094
Why Horizon Global Shares Are Trading Higher By Over 340%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Benzinga · 01/03 18:39
Navidea stock soars ~25% on upcoming US patent linked to cancer drug pipeline
Seeking Alpha · 01/03 14:54
BRIEF-Navidea Biopharmaceuticals Announces Notice Of Allowance For U.S. Patent Application
Reuters · 01/03 13:43
Navidea Biopharmaceuticals Announces The Notice Of Allowance For U.S. Patent Application For Key Component Of The Company's Cancer Immunotherapy Pipeline
Benzinga · 01/03 13:34
Why Silo Pharma Shares Are Trading Higher By Around 64%? Here Are 46 Stocks Moving In Friday's Mid-Day Session
Benzinga · 12/30/2022 17:28
Reported Late Wednesday, Navidea Biopharmaceuticals Files Appeal In CRG Case
Benzinga · 12/01/2022 06:02
Navidea Biopharmaceuticals Files Appeal in CRG Case
DUBLIN, Ohio, December 01, 2022--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that on November 29, 202...
Business Wire · 12/01/2022 01:04
Navidea Biopharmaceuticals Announces 50th Participant Enrolled In The Company's Phase 3 Trial In Rheumatoid Arthritis
Benzinga · 11/28/2022 13:31
Notable earnings after Tuesday's close
Seekingalpha · 11/14/2022 22:35
BRIEF-Navidea Biopharmaceuticals Reports Q3 Financial Results
Reuters · 11/14/2022 18:16
Navidea Biopharm GAAP EPS of -$0.25, revenue of $0.08M
Seekingalpha · 11/14/2022 13:47
Navidea Biopharmaceuticals Reports Third Quarter 2022 Financial Results
DUBLIN, Ohio, November 14, 2022--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced its financial results fo...
Business Wire · 11/14/2022 13:00
Navidea Biopharmaceuticals Announces Acceptance of Abstract for Presentation at Upcoming Society for Immunotherapy of Cancer Annual Meeting
DUBLIN, Ohio, October 05, 2022--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that results from the Com...
Business Wire · 10/05/2022 20:30
Navidea Biopharmaceuticals Tapped for Presentation at November Cancer Conference
Navidea Biopharmaceuticals Tapped for Presentation at November Cancer Conference
MT Newswires · 10/05/2022 17:12
BRIEF-Navidea Biopharmaceuticals Appoints Joshua Wilson To The Board Of Directors Announces Dates Related To Its 2022 Annual Meeting Of Stockholders
BRIEF-Navidea Biopharmaceuticals Appoints Joshua Wilson To The Board Of Directors Announces Dates Related To Its 2022 Annual Meeting Of Stockholders
Reuters · 09/30/2022 12:37
Why ZW Data Action Technologies Jumped 37%; Here Are 71 Biggest Movers From Yesterday
Gainers
Benzinga · 09/16/2022 08:38
Why Adobe Is Trading Lower By 17%, Here Are 49 Stocks Moving In Thursday's Mid-Day Session
Gainers HeartBeam, Inc. (NASDAQ: BEAT) shares surged 58% to $1.96 after the company announced its patent for a 12-lead electrocardiogram patch monitor intended for detection of acute coronary syndrome and cardiac arrhythmia was issued by the USPTO.
Benzinga · 09/15/2022 17:03
Why Kaspien Holdings Is Trading Lower By 13%; Here Are 21 Stocks Moving Premarket
Gainers Aditxt, Inc. (NASDAQ: ADTX) rose 54.3% to $28.56 in pre-market trading following effect of 1:50 reverse stock split.
Benzinga · 09/14/2022 10:19
Notable earnings after Thursday's close
Major earnings expected after the bell on Thursday include: DocuSign (DOCU) Zscaler (<a href="https:...
Seekingalpha · 09/07/2022 21:35
BRIEF-Navidea Biopharmaceuticals Ends Binding MoU With Jubilant Radiopharma
BRIEF-Navidea Biopharmaceuticals Ends Binding MoU With Jubilant Radiopharma
Reuters · 09/01/2022 12:42
More
Webull provides a variety of real-time NAVB stock news. You can receive the latest news about Navidea Biopharm through multiple platforms. This information may help you make smarter investment decisions.
About NAVB
Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The Company is developing multiple precision-targeted products based on its Manocept platform to enhance patient care by identifying the sites and pathways of undetected disease. Its business is focused on two primary types of drug products, such as diagnostic substances, including Tc99m tilmanocept and other diagnostic applications of its Manocept platform, and therapeutic development programs, including therapeutic applications of its Manocept platform. The Company has developed processes for producing the first two therapeutic Manocept immuno-construct series, the Manocept doxorubicin (MAN-DOX) series, which targets activated CD206+ macrophages, and the Manocept dexamethasone (MAN-DEX) series, which inhibits the inflammatory activity of activated CD206+ macrophages.